Séverine Guiu1, Céline Charon-Barra2, Déwi Vernerey3, Pierre Fumoleau4, Mario Campone5, Marc Spielmann6, Henri Roché7, Christel Mesleard8, Laurent Arnould2, Jérôme Lemonnier8, Magali Lacroix-Triki9. 1. Department of Medical Oncology, Institut du Cancer de Montpellier, 208 avenue des Apothicaires, 34298 Montpellier Cedex 5, France. 2. Department of Pathology, Georges-François Leclerc Cancer Center, 1 rue du Professeur Marion, 21000 Dijon, France. 3. Methodological and Quality of Life in Oncology Unit, EA 3181, University Hospital of Besançon, 2 place Saint-Jacques, 25000 Besançon, France. 4. Department of Medical Oncology, Georges-François Leclerc Cancer Center, 1 rue du Professeur Marion, 21000 Dijon, France. 5. Department of Medical Oncology, ICO Centre René Gauducheau, boulevard Jacques Monod, 44805 Saint Herblain, France. 6. Department of Medical Oncology, Institut Gustave Roussy, 114 rue Edouard-Vaillant, 94800 Villejuif, France. 7. Department of Medical Oncology, Institut Claudius Régaud, 20/24 Rue du Pont Saint Pierre, 31300 Toulouse, France. 8. R&D UNICANCER, 101 rue de Tolbiac, 75654 Paris, France. 9. Department of Pathology, Institut Claudius Régaud, 20/24 rue du Pont Saint Pierre, 31300 Toulouse, France.
Abstract
AIM: Microarray studies identified a subgroup of molecular apocrine tumors (estrogen receptor [ER] negative/androgen receptor [AR] positive) that express luminal genes including FOXA1. FOXA1 may direct AR to sites normally occupied by ER in luminal tumors, inducing an estrogen-like gene program that stimulated proliferation. MATERIALS & METHODS: Expression of AR and FOXA1 was evaluated by immunohistochemistry in 592 patients with nonmetastatic triple-negative breast cancer (TNBC). RESULTS: Coexpression of AR and FOXA1 was found in 15.2% of patients. These tumors were more frequently lobular, found in older patients and exhibited a lower nuclear grade and a greater degree of node involvement. They less often exhibited lymphocytic infiltrate, pushing margins, syncytial architecture, central fibrosis or necrosis. CONCLUSION: TNBC with coexpression of AR and FOXA1 seems to behave like luminal tumors with a morphological profile distinct from other TNBC. These biomarkers could be useful to identify a subgroup of TNBC and could have future therapeutic implications.
AIM: Microarray studies identified a subgroup of molecular apocrine tumors (estrogen receptor [ER] negative/androgen receptor [AR] positive) that express luminal genes including FOXA1. FOXA1 may direct AR to sites normally occupied by ER in luminal tumors, inducing an estrogen-like gene program that stimulated proliferation. MATERIALS & METHODS: Expression of AR and FOXA1 was evaluated by immunohistochemistry in 592 patients with nonmetastatic triple-negative breast cancer (TNBC). RESULTS: Coexpression of AR and FOXA1 was found in 15.2% of patients. These tumors were more frequently lobular, found in older patients and exhibited a lower nuclear grade and a greater degree of node involvement. They less often exhibited lymphocytic infiltrate, pushing margins, syncytial architecture, central fibrosis or necrosis. CONCLUSION: TNBC with coexpression of AR and FOXA1 seems to behave like luminal tumors with a morphological profile distinct from other TNBC. These biomarkers could be useful to identify a subgroup of TNBC and could have future therapeutic implications.
Entities:
Keywords:
FOXA1; androgen receptor; molecular apocrine tumors; triple-negative breast cancer
Authors: Takeo Fujii; James M Reuben; Lei Huo; Jose Rodrigo Espinosa Fernandez; Yun Gong; Rachel Krupa; Mahipal V Suraneni; Ryon P Graf; Jerry Lee; Stephanie Greene; Angel Rodriguez; Lyndsey Dugan; Jessica Louw; Bora Lim; Carlos H Barcenas; Angela N Marx; Debu Tripathy; Yipeng Wang; Mark Landers; Ryan Dittamore; Naoto T Ueno Journal: PLoS One Date: 2017-09-28 Impact factor: 3.240